Kathryn A Colby1, Euna B Koo. 1. Cornea and Refractive Surgery, Massachusetts Eye and Ear Infirmary, Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts 02114, USA. KAColby@meei.harvard.edu
Abstract
PURPOSE OF REVIEW: To review emerging indications for the Boston keratoprosthesis (KPro) and to discuss current research underway to improve clinical outcomes. RECENT FINDINGS: In addition to multiple failed corneal grafts, other ocular conditions for which the Boston KPro has been used include herpetic keratitis, aniridia, autoimmune ocular disorders, and pediatric corneal opacities. In the recent years, the KPro has been implanted for various other conditions and has also been explored as a cost-effective treatment for severe corneal diseases internationally. Cicatricial and inflammatory ocular conditions remain the most difficult cases for KPro use but studies investigating various immunomodulators and biologic materials for improved retention are ongoing. Postoperative management of glaucoma is critical for preserving the visual gains achieved with the Boston KPro. Current studies are evaluating novel devices for intraocular pressure measurement. SUMMARY: Accrued experience with the Boston KPro has demonstrated its versatility but also the difficulties that remain in postoperative management. With many studies underway to improve cost-effectiveness, intra-operative and postoperative management, keratoprostheses will be made increasingly available to those countries most in need.
PURPOSE OF REVIEW: To review emerging indications for the Boston keratoprosthesis (KPro) and to discuss current research underway to improve clinical outcomes. RECENT FINDINGS: In addition to multiple failed corneal grafts, other ocular conditions for which the Boston KPro has been used include herpetic keratitis, aniridia, autoimmune ocular disorders, and pediatric corneal opacities. In the recent years, the KPro has been implanted for various other conditions and has also been explored as a cost-effective treatment for severe corneal diseases internationally. Cicatricial and inflammatory ocular conditions remain the most difficult cases for KPro use but studies investigating various immunomodulators and biologic materials for improved retention are ongoing. Postoperative management of glaucoma is critical for preserving the visual gains achieved with the Boston KPro. Current studies are evaluating novel devices for intraocular pressure measurement. SUMMARY: Accrued experience with the Boston KPro has demonstrated its versatility but also the difficulties that remain in postoperative management. With many studies underway to improve cost-effectiveness, intra-operative and postoperative management, keratoprostheses will be made increasingly available to those countries most in need.
Authors: Jonathan L Hager; David L Phillips; Kenneth M Goins; Anna S Kitzmann; Mark A Greiner; Alex W Cohen; Jeffrey D Welder; Michael D Wagoner Journal: Int Ophthalmol Date: 2015-05-16 Impact factor: 2.031
Authors: Maria Fideliz de la Paz; Josef Stoiber; Valeria de Rezende Couto Nascimento; Juan Alvarez de Toledo; Orang Seyeddain; Wolfgang Hitzl; Günther Grabner; Rafael I Barraquer; Ralph Michael Journal: Graefes Arch Clin Exp Ophthalmol Date: 2013-10-25 Impact factor: 3.117
Authors: Fang Chen; David C Mundy; Peter Le; Youngyoon Amy Seo; Caitlin M Logan; Gabriella Maria Fernandes-Cunha; Chris A Basco; David Myung Journal: Transl Vis Sci Technol Date: 2022-10-03 Impact factor: 3.048
Authors: Lee Kiang; Mark I Rosenblatt; Rachel Sartaj; Ana G Alzaga Fernandez; Szilard Kiss; Nathan M Radcliffe; Donald J D'Amico; Kimberly C Sippel Journal: Graefes Arch Clin Exp Ophthalmol Date: 2012-02-28 Impact factor: 3.117
Authors: Borja Salvador-Culla; Kyung Jae Jeong; Paraskevi Evi Kolovou; Homer H Chiang; James Chodosh; Claes H Dohlman; Daniel S Kohane Journal: Transl Vis Sci Technol Date: 2016-04-28 Impact factor: 3.283
Authors: Ana G Alzaga Fernandez; Nathan M Radcliffe; Kimberly C Sippel; Mark I Rosenblatt; Priyanka Sood; Christopher E Starr; Jessica B Ciralsky; Donald J D'Amico; Szilárd Kiss Journal: Clin Ophthalmol Date: 2012-08-27